Abstract
Programmed cell death 5 (PDCD5) was first identified as a gene upregulated in cells undergoing apoptosis. We recently demonstrated the inhibitory effect of PDCD5 on experimentally induced autoimmune encephalomyelitis. In this study, we investigated the anti-inflammatory effects of recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced arthritis (CIA) model. We find that vaccination of collagen II (CII) induced CIA rats with rhPDCD5 significantly delayed the occurrence and reduced the severity of CIA rats. rhPDCD5 also restored the loss of Foxp3(+) regulatory T (Treg) cells and decreased the population of Th1 and Th17 in CIA rats. Simultaneously, rhPDCD5 treatment suppressed the production of pro-inflammatory cytokines (interleukin (IL)-6, IL-17A, tumor necrosis factor-α (TNF-α), and interferon gamma (IFN-γ)) and increased the secretion of anti-inflammatory cytokines (transforming growth factor beta 1 (TGF-β1) and IL-10) in CIA rats. In addition, rhPDCD5 inhibited the ability of CII to induce proliferation of splenocytes and lymph node cells (LNCs) and promoted the CII-activated CD4(+) cell apoptosis. These results of rhPDCD5-treated CIA rats were similar with those of recombinant human TNF-α receptor IgG Fc (rhTNFR:Fc). Thus, to our knowledge, we provide the first evidence that rhPDCD5 may be an efficient approach to diminishing exacerbated immune responses in CIA, indicating its therapeutic potential in the treatment of rheumatoid arthritis and other autoimmune diseases.
Introduction
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by an imbalance in T-cell populations: an excess of effector cells (Th1 and Th17) drives inflammation, while a deficiency in regulatory T cells (Tregs) prevents the resolution of the immune response. While biological therapies like TNF-alpha inhibitors have revolutionized RA treatment, their high cost and potential for serious side effects or non-responsiveness highlight the need for novel therapies that restore immune tolerance. PDCD5, a protein involved in programmed cell death, has shown promise as an immunomodulator. This study explores the therapeutic potential of recombinant human PDCD5 (rhPDCD5) in a rat model of arthritis.
Methods
Researchers utilized the Collagen-Induced Arthritis (CIA) model in Wistar rats, which closely mimics human RA. Rats were divided into four cohorts: a healthy control, an untreated arthritic group (CIA+OVA), a group treated with a standard TNF-alpha inhibitor (rhTNFR:Fc), and the experimental group treated with rhPDCD5 (14 mg/kg). Evaluation metrics included clinical scoring of paw swelling and joint rigidity, histological analysis of bone and cartilage, flow cytometry for T-cell subset quantification, and ELISA for cytokine profiling.
Results
The administration of rhPDCD5 significantly delayed the onset and reduced the severity of arthritis in CIA rats. Clinical scores, which quantify joint damage and swelling, were markedly lower in the rhPDCD5-treated group compared to untreated rats.
Visual inspection of the paws confirmed these quantitative findings. While untreated CIA rats exhibited massive swelling and redness, those treated with rhPDCD5 showed significantly preserved joint morphology.
Mechanistically, rhPDCD5 restored the population of Foxp3+ Treg cells (increasing from ~7.8% to ~13.1% in lymph nodes) and suppressed inflammatory Th17 cells. This shift was accompanied by a "cytokine flip," where pro-inflammatory markers (IL-6, TNF-α, IL-17A) decreased and anti-inflammatory markers (IL-10, TGF-β1) increased. Furthermore, rhPDCD5 appeared to "prime" auto-reactive T cells for apoptosis, selectively reducing the cells attacking joint collagen.
Discussion and Conclusion
The results demonstrate that rhPDCD5 is a potent immunomodulator capable of restoring immune homeostasis in arthritic rats. Its efficacy is comparable to established TNF-alpha inhibitors, suggesting it could serve as a viable alternative or adjunct therapy. Unlike broad immunosuppressants, rhPDCD5 promotes the restoration of regulatory T cells and the selective apoptosis of self-reactive cells.
Future research should investigate the impact of rhPDCD5 on B-cell responses and auto-antibody production. Additionally, while the results in rats are promising, clinical translation will require rigorous safety testing to ensure that systemic administration does not adversely affect normal apoptotic processes in other tissues. In conclusion, rhPDCD5 represents a significant step toward developing therapies that restore immune tolerance in rheumatoid arthritis.
Summary updated